EXELON
LOE ApproachingNDAORALCAPSULE
Approved
Apr 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
5/8 — Partial
EXELON by Novartis is unknown, it is thought to exert its therapeutic effect by enhancing cholinergic function. Approved for dementia of the alzheimer’s type (ad), mild-to-moderate dementia associated with parkinson’s disease (pdd). First approved in 2000.
Drug data last refreshed 9m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EXELON (rivastigmine) is an oral small-molecule cholinesterase inhibitor approved for Alzheimer's dementia and Parkinson's disease dementia. It enhances cholinergic function by reversibly inhibiting acetylcholine hydrolysis, increasing acetylcholine concentration in the brain. The drug does not alter the underlying disease course and loses efficacy as neuronal degeneration progresses.
$20MPart D
LOE ApproachingProduct approaching loss of exclusivity signals transition from growth-stage marketing to LOE mitigation strategies and potential right-sizing of commercial teams.
Mechanism of Action
unknown, it is thought to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by cholinesterase. The effect of rivastigmine may lessen as the disease process advances…
Worked on EXELON at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.